Induction of intercrypt goblet cells upon bacterial infection: a promising therapeutic target to restore the mucosal barrier

Intestinal mucins play a crucial role in the mucosal barrier, serving as the body’s initial defense against microorganisms. However, how the host regulates the secretion and glycosylation of these mucins in response to bacterial invasion remains unclear. Our study demonstrates that when exposed to S...

Full description

Saved in:
Bibliographic Details
Main Authors: Renaud Léonard, Ewa Pasquereau-Kotula, Edwige Madec, Benjamin Marsac, Adriana Mihalache, Laurence du Merle, Jordan Denis, Corentin Spriet, Philippe Sansonetti, Shaynoor Dramsi, Catherine Robbe Masselot
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Gut Microbes
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/19490976.2024.2426609
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intestinal mucins play a crucial role in the mucosal barrier, serving as the body’s initial defense against microorganisms. However, how the host regulates the secretion and glycosylation of these mucins in response to bacterial invasion remains unclear. Our study demonstrates that when exposed to Streptococcus gallolyticus (SGG), a gut pathobiont, the host mucosa promptly adjusts the behavior of specialized goblet cells (GCs) located in the middle of the crypts. A subset of these cells undergoes a remodeling, becoming intercrypt goblet cells (icGCs), which do not detach from the surface but instead migrate along intercrypt spaces while secreting a mucus impermeable to bacterial pathogens. Significantly, a non-piliated SGG mutant unable to bind to mucus fails to induce icGCs, allowing its translocation through the mucosa and submucosa. Interestingly, a closely related nonpathogenic bacterium, SGM, able to bind to mucus, also triggers the differentiation of GCs into icGCs. This discovery opens new avenues for treating patients with a “leaky gut” as observed in intestinal diseases such as inflammatory bowel diseases and metabolic disorders, but also patients with a history of repeated antibiotic use. Utilizing mucus-adherent probiotics to induce icGCs represents a promising strategy for reinforcing the mucosal barrier.
ISSN:1949-0976
1949-0984